Compare Amylx Pharmaceuticals Inc (AMLX) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Novartis AG — how do they compare? Amylx Pharmaceuticals Inc trades at $23.96 (market cap $2.64B), while Novartis AG trades at $152.38 (market cap $295.37B). The key difference: Novartis AG is far larger — about 111.9× Amylx Pharmaceuticals Inc's market cap, and Novartis AG pays a 3.07% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | NVS | |
|---|---|---|
Market Cap | $2.64B | $295.37B |
Sector | Health | Health |
52-Week High | $24.19 | $168.62 |
52-Week Low | $7.82 | $119.31 |
Enterprise Value | $2.39B | $336.69B |
Dividend Yield | — | 3.07% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
